Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

about

A 'reluctant' critical review: 'Manual for evidence-based clinical practice (2015)'.

P2860

Q38685671-EA680880-C902-4ACC-94E0-5D6186036987

P2860

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Item

http://www.wikidata.org/entity/Q38200587

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Benefit-risk assessment of dab ...... -valvular atrial fibrillation.

@en

type

Item

label

Benefit-risk assessment of dab ...... -valvular atrial fibrillation.

@en

prefLabel

Benefit-risk assessment of dab ...... -valvular atrial fibrillation.

@en

P1476

Benefit-risk assessment of dab ...... -valvular atrial fibrillation.

@en

P2093

Sascha Meyer Dos Santos

http://www.w3.org/2001/XMLSchema#string

Sebastian Harder

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons

Structure-based design of novel potent nonpeptide thrombin inhibitors

A specific antidote for dabigatran: functional and structural characterization

Dabigatran versus warfarin in patients with atrial fibrillation

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

Validation of Clinical Classification Schemes for Predicting Stroke

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

P2888

s40264-014-0151-1

P304

295-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40264-014-0151-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028655213

http://www.w3.org/2001/XMLSchema#string

P698

24683059

http://www.w3.org/2001/XMLSchema#string

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

about

P2860

P2860

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698